Auris Health, Inc., a Redwood City, CA-based developer of robotic interventional technology, closed a $220m equity financing.
The round was led by Partner Fund Management, with participation from new investors Wellington Management, D1 Capital Partners and Senator Investment Group and existing investors Mithril Capital, Lux Capital and Viking Global Investors.
The company, which has now raised more than $700 million to date, intends to use the funds to advance the commercialization of its Monarch™ Platform and the development of robotic interventional technology.
Led by Frederic Moll, M.D., founder and CEO, Auris Health is developing platforms that enhance physician capabilities, evolve minimally invasive techniques, and create new categories of care for optimal patient outcomes by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform.
The Monarch Platform is currently FDA-cleared for diagnostic and therapeutic bronchoscopic procedures. The system utilizes a familiar controller interface to navigate a flexible robotic endoscope to the periphery of the lung. Combining traditional endoscopic views with computer-assisted navigation based on patient-specific 3-D models, the platform provides physicians with continuous bronchoscope vision, computed guidance and precise instrument control throughout the entire procedure.